| | | | | | | | | | | | | | | | | | | | | | |
Ownership Document
|
| Schema Version: X0306 |
| Document Type: 4/A |
| Period of Report: 9/1/20 |
| Date of Original Submission: 9/3/20 |
| Not Subject to Section 16: 0 |
| Issuer: |
| Issuer CIK: 1411690 |
| Issuer Name: Bionano Genomics, Inc |
| Issuer Trading Symbol: BNGO |
| Reporting Owner: |
| Reporting Owner ID: |
| | Owner CIK: 1821605 |
| | Owner Name: Chaubey Alka |
| Reporting Owner Address: |
| | Owner Street 1: C/O BIONANO GENOMICS, INC. |
| | Owner Street 2: 9540 TOWNE CENTRE DRIVE, SUITE 100 |
| | Owner City: SAN DIEGO |
| | Owner State: CA |
| | Owner ZIP Code: 92121 |
| | Owner State Description: |
| Reporting Owner Relationship: |
| | Is Director? No |
| | Is Officer? Yes |
| | Is Ten Percent Owner? No |
| | Is Other? No |
| | Officer Title: Chief Medical Officer |
| Derivative Table: |
| Derivative Transaction: |
| | Security Title: |
| | | Value: Stock Option (Right to Buy) |
| | Conversion or Exercise Price: |
| | | Value: 0.56 |
| | Transaction Date: |
| | | Value: 9/1/20 |
| | Deemed Execution Date: |
| | Transaction Coding: |
| | | Transaction Form Type: 4 |
| | | Transaction Code: A |
| | | Equity Swap Involved? No |
| | Transaction Timeliness: |
| | | Value: |
| | Transaction Amounts: |
| | | Transaction Shares: |
| Value: 300,000 |
| | | Transaction Price Per Share: |
| Value: 0.00 |
| | | Transaction Acquired-Disposed Code: |
| Value: A |
| | Exercise Date: |
| | | Footnote ID: F1 |
| | Expiration Date: |
| | | Value: 9/1/30 |
| | Underlying Security: |
| | | Underlying Security Title: |
| Value: Common Stock |
| | | Underlying Security Shares: |
| Value: 300,000 |
| | Post-Transaction Amounts: |
| | | Shares Owned Following Transaction: |
| Value: 300,000 |
| | Ownership Nature: |
| | | Direct or Indirect Ownership: |
| Value: D |
| Footnotes: |
| Footnote - F1: 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. |
| Remarks: The Form 4 is being amended for the sole purpose to change a typographical error in the exercise price of derivative security in column 2 of Table II. |
| Owner Signature: |
| Signature Name: /s/ R. Erik Holmlin, Attorney-in-Fact |
| Signature Date: 9/3/20 |
